An investigation on behalf of investors in ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) shares over potential wrongdoing at ZIOPHARM Oncology, Inc. was announced.
San Diego, CA -- (SBWIRE) -- 08/31/2018 -- An investigation was announced for investors in shares of ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) concerning potential breaches of fiduciary duties by certain officers and directors at ZIOPHARM Oncology, Inc.
Investors, who purchased shares of ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain ZIOPHARM Oncology, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
Boston, MA based ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. Shares of ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) declined to as low as $2.23 per share on August 6, 2018.
On August 30, 2018, NASDAQ: ZIOP shares closed at $2.75 per share.
Those who purchased shares of ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels